# 36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Sodium Risedronate 75 mg Tablets

> **NCT02106442** · — · COMPLETED · sponsor: **Takeda** · enrollment: 579 (actual)

## Conditions studied

- Osteoporosis

## Interventions

- **DRUG:** Sodium risedronate

## Key facts

- **NCT ID:** NCT02106442
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05-13
- **Primary completion:** 2018-04-30
- **Final completion:** 2018-04-30
- **Target enrollment:** 579 (ACTUAL)
- **Last updated:** 2019-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02106442

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02106442, "36-month Special Drug Use Surveillance on Frequency of Bone Fractures With Sodium Risedronate 75 mg Tablets". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02106442. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*